All Lots of Liptruzet in U.S. Recalled Over Packaging Defect — Physician’s First Watch
All Lots of Liptruzet in U.S. Recalled Over Packaging Defect
By Larry Husten
All lots of the combination cholesterol-lowering drug Liptruzet (ezetimibe and atorvastatin) in the U.S. are being recalled because a packaging defect could allow air and moisture to affect the quality of the drug, Merck announced on Tuesday.
The company noted that "the likelihood of the packaging defects decreasing the effectiveness of Liptruzet on a patient's lipid profile or negatively impacting the safety of the product is remote." To date, no adverse events or product complaints have been reported.
Merck is recalling the drug from U.S. wholesalers but is not asking patients or pharmacies to return their stock; patients may continue taking pills already in their possession.
Adapted with permission from CardioExchange.